Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of patients previously exposed to lentiviral-based CD19 CAR T-cell therapy
NL-OMON53025Recruiting
- Sponsor
- Novartis
- Start
- Apr 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of anti-CD19 CAR-T cell therapy in B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), mature B-cell lymphoma and 1 more, sponsored by Novartis. Primary endpoint: Selected delayed adverse events related to prior CD19 CAR T-cell therapy. Started Apr 2020; status: recruiting.
02
Drugs
anti-CD19 CAR-T cell therapy
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON53025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53025.